| Literature DB >> 34099045 |
Tsu-Ming Chien1,2,3, Yen-Man Lu2,3,4, Ching-Chia Li2,3, Wen-Jeng Wu1,2,3, Hsueh-Wei Chang5,6,7, Yii-Her Chou8,9,10.
Abstract
BACKGROUND: Urolithiasis is considered a vital public health issue with a substantial burden on kidney function. Additionally, only few reports focused on the gender difference in patients with urolithiasis. Therefore, this study aimed to compare the clinical characteristics of sex difference and their potential risk for chronic kidney disease (CKD) in patients with urolithiasis.Entities:
Keywords: Chronic kidney disease; Gender; Urolithiasis
Mesh:
Substances:
Year: 2021 PMID: 34099045 PMCID: PMC8185917 DOI: 10.1186/s13293-021-00382-3
Source DB: PubMed Journal: Biol Sex Differ ISSN: 2042-6410 Impact factor: 5.027
Basic characteristics according to gender (N = 1802)
| Variables | Total (N = 1802) | Men (N = 1312) | Women (N = 490) | ||||
|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | N | (%) | ||
| Age (years) | |||||||
| > 50 | 1158 | (64.2) | 828 | (45.9) | 330 | (67.3) | < 0.001 |
| > 60 | 634 | (35.2) | 464 | (35.4) | 170 | (34.7) | 0.790 |
| Comorbidities | |||||||
| Hypertension | 691 | (38.3) | 500 | (38.1) | 191 | (39.0) | 0.735 |
| Diabetes | 280 | (15.5) | 151 | (11.5) | 129 | (26.3) | < 0.001 |
| Dyslipidemia | 150 | (8.3) | 93 | (7.1) | 57 | (11.6) | 0.002 |
| Gout | 367 | (20.4) | 293 | (22.5) | 74 | (15.1) | 0.001 |
| Hyperuricemia | 267 | (14.8) | 197 | (15.0) | 70 | (14.3) | 0.698 |
| Obesity (BMI > 27) | 446 | (24.8) | 322 | (24.5) | 124 | (25.3) | 0.738 |
| Stone composition | |||||||
| CaO | 1109 | (61.5) | 844 | (64.3) | 265 | (54.1) | < 0.001 |
| CaO-CaP | 165 | (9.2) | 114 | (8.7) | 51 | (10.4) | 0.260 |
| Apatite | 280 | (15.5) | 147 | (11.2) | 133 | (27.1) | < 0.001 |
| Brushite | 11 | (0.6) | 9 | (0.7) | 2 | (0.4) | 0.501 |
| Uric acid | 126 | (7.0) | 105 | (8.0) | 21 | (4.3) | 0.006 |
| Struvite | 108 | (6.0) | 91 | (7.0) | 17 | (3.4) | 0.005 |
| Cystine | 3 | (0.2) | 2 | (0.2) | 1 | (0.2) | 0.811 |
| Surgery of stone acquisition | |||||||
| PCNL | 349 | (19.4) | 237 | (18.0) | 112 | (22.8) | 0.022 |
| URSL | 846 | (46.9) | 573 | (43.7) | 273 | (55.7) | < 0.001 |
| Cystolithotripsy | 374 | (20.8) | 335 | (25.5) | 39 | (8.0) | < 0.001 |
| Self-voiding after ESWL | 181 | (10.0) | 124 | (9.5) | 57 | (11.6) | 0.170 |
| Self-voiding | 52 | (2.9) | 33 | (2.5) | 19 | (3.8) | 0.124 |
BMI, body mass index; CaO, calcium oxalate; CaP, calcium phosphate; PCNL, percutaneous nephrolithotomy; URSL, ureteroscopic lithotripsy; ESWL, extracorporeal shock wave lithotripsy; SD, standard deviation; SG, specific gravity; eGFR, estimated glomerular filtration rate
Fig. 1Proportions of stone compositions in different age groups and genders
Basic characteristics according to long-term renal function
| Variables | eGFR < 60 (N = 94) | eGFR ≥ 60 (N = 1708) | |||
|---|---|---|---|---|---|
| N | (%) | N | (%) | ||
| Age > 60 | 74 | (78.7) | 560 | (32.8) | < 0.001 |
| Female gender | 59 | (62.8) | 431 | (25.2) | < 0.001 |
| Comorbidities | |||||
| Hypertension | 51 | (54.2) | 640 | (37.4) | < 0.001 |
| Diabetes | 42 | (44.7) | 238 | (13.9) | < 0.001 |
| Dyslipidemia | 8 | (8.5) | 142 | (8.3) | 0.946 |
| Gout | 19 | (20.2) | 348 | (20.5) | 0.952 |
| Hyperuricemia | 19 | (20.2) | 248 | (14.5) | 0.130 |
| Obesity (BMI > 27) | 29 | (30.9) | 417 | (24.4) | 0.159 |
| Stone composition | |||||
| Uric acid | 21 | (22.3) | 138 | (8.1) | < 0.001 |
| Surgery of stone acquisition | |||||
| PCNL | 27 | (28.7) | 322 | (18.9) | 0.019 |
| URSL | 52 | (55.3) | 794 | (46.4) | 0.095 |
| Cystolithotripsy | 6 | (6.4) | 368 | (21.5) | < 0.001 |
| Self-voiding after ESWL | 1 | (1.0) | 180 | (10.5) | 0.003 |
BMI, body mass index; PCNL, percutaneous nephrolithotomy; URSL, ureteroscopic lithotripsy; SD, standard deviation, SG, specific gravity
Independent risk factors for poor kidney function
| Variables | Odds ratio | 95% CI |
|---|---|---|
| Age (year) | ||
| > 60 | 6.36 | 3.8–10.8 |
| Gender | ||
| Female/male | 5.31 | 3.3–8.4 |
| Stone composition | ||
| Uric acid/nonuric acid | 3.55 | 2.0–6.4 |
| Comorbidities | ||
| Hypertension | 7.20 | 3.8–13.7 |
| Diabetes | 7.06 | 3.1–16.2 |